Baxter International Inc
BAX31.405USD
+0.234+0.75%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
16.05BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Baxter International Inc Unternehmen
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
Unternehmensinformationen
Unternehmens-codeBAX
Name des UnternehmensBaxter International Inc
IPO-datumMay 15, 1961
Gegründet am1931
CEOMr. D. Brent Shafer
Anzahl der mitarbeiter38000
WertpapierartOrdinary Share
GeschäftsjahresendeMay 15
AddresseOne Baxter Parkway
StadtDEERFIELD
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl60015
Telefon12249482000
Websitehttps://www.baxter.com/
Unternehmens-codeBAX
IPO-datumMay 15, 1961
Gegründet am1931
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Heather Knight
Ms. Heather Knight
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies
177.32K
+11.79%
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. Alok Sonig
Mr. Alok Sonig
Executive Vice President, Group President - Pharmaceuticals
Executive Vice President, Group President - Pharmaceuticals
130.30K
+15.20%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
118.15K
+10.70%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
28.52K
+2.77%
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
23.05K
+2.74%
Ms. Patricia B. Morrison
Ms. Patricia B. Morrison
Independent Director
Independent Director
15.76K
-25.89%
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Director
Independent Director
9.27K
+2.46%
Mr. Jeffrey A. (Jay) Craig
Mr. Jeffrey A. (Jay) Craig
Independent Director
Independent Director
3.47K
--
Ms. Nancy M. Schlichting
Ms. Nancy M. Schlichting
Lead Independent Director
Lead Independent Director
787.00
-88.29%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Heather Knight
Ms. Heather Knight
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies
177.32K
+11.79%
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. Alok Sonig
Mr. Alok Sonig
Executive Vice President, Group President - Pharmaceuticals
Executive Vice President, Group President - Pharmaceuticals
130.30K
+15.20%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
118.15K
+10.70%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
28.52K
+2.77%
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
23.05K
+2.74%
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Infusion Therapies and Technologies
4.10B
38.58%
Care and Connectivity Solutions
1.81B
17.06%
Injectables and Anesthesia
1.37B
12.91%
Front Line Care
1.14B
10.69%
Advanced Surgery
1.10B
10.38%
Other
1.10B
10.39%
Nach RegionUSD
Name
Umsatz
Anteil
United States
5.85B
55.00%
International
4.79B
45.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Infusion Therapies and Technologies
4.10B
38.58%
Care and Connectivity Solutions
1.81B
17.06%
Injectables and Anesthesia
1.37B
12.91%
Front Line Care
1.14B
10.69%
Advanced Surgery
1.10B
10.38%
Other
1.10B
10.39%
Aktionäre
Update-Zeit: 16 hours ago
Update-Zeit: 16 hours ago
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
11.80%
Dodge & Cox
10.06%
Pzena Investment Management, LLC
6.56%
BlackRock Institutional Trust Company, N.A.
5.76%
State Street Global Advisors (US)
4.25%
Other
61.58%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
11.80%
Dodge & Cox
10.06%
Pzena Investment Management, LLC
6.56%
BlackRock Institutional Trust Company, N.A.
5.76%
State Street Global Advisors (US)
4.25%
Other
61.58%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
53.40%
Investment Advisor
32.35%
Research Firm
2.70%
Hedge Fund
2.37%
Pension Fund
2.23%
Insurance Company
1.44%
Bank and Trust
1.13%
Sovereign Wealth Fund
1.00%
Individual Investor
0.36%
Other
3.01%
Institutionelle Beteiligung
Update-Zeit: Thu, Feb 20
Update-Zeit: Thu, Feb 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
1902
499.25M
97.33%
-40.58M
2024Q4
1984
501.11M
97.98%
-41.68M
2024Q3
2005
485.40M
95.14%
-42.32M
2024Q2
2042
472.72M
92.77%
-47.98M
2024Q1
2091
469.13M
92.11%
-57.76M
2023Q4
2137
471.69M
92.98%
-44.04M
2023Q3
2123
465.39M
91.91%
-35.52M
2023Q2
2140
458.55M
90.66%
-30.65M
2023Q1
2123
459.27M
90.86%
-22.24M
2022Q4
2132
456.58M
90.57%
-21.28M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
60.53M
11.8%
+468.84K
+0.78%
Dec 31, 2024
Dodge & Cox
51.58M
10.06%
+1.20M
+2.39%
Feb 28, 2025
Pzena Investment Management, LLC
33.64M
6.56%
+1.42M
+4.39%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
29.53M
5.76%
-652.43K
-2.16%
Dec 31, 2024
State Street Global Advisors (US)
21.79M
4.25%
+12.21K
+0.06%
Dec 31, 2024
BlackRock Financial Management, Inc.
17.57M
3.43%
+1.23M
+7.54%
Dec 31, 2024
T. Rowe Price Associates, Inc.
15.25M
2.97%
+1.13M
+8.03%
Dec 31, 2024
Geode Capital Management, L.L.C.
12.45M
2.43%
+290.28K
+2.39%
Dec 31, 2024
Harris Associates L.P.
8.46M
1.65%
-1.31M
-13.43%
Dec 31, 2024
Columbia Threadneedle Investments (US)
7.28M
1.42%
-2.29M
-23.93%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
Parnassus Value Select ETF
5.07%
Cullen Enhanced Equity Income ETF
3.53%
iShares Large Cap Value Active ETF
2.45%
Global X S&P 500 Quality Dividend ETF
2%
iShares U.S. Medical Devices ETF
1.92%
Invesco S&P 500 Equal Weight Health Care ETF
1.76%
SPDR S&P Health Care Equipment ETF
1.52%
First Trust Indxx Medical Devices ETF
1.27%
ROBO Global Healthcare Technology & Innovation ETF
0.98%
Humankind US Stock ETF
0.85%
Mehr Anzeigen
Parnassus Value Select ETF
Anteil5.07%
Cullen Enhanced Equity Income ETF
Anteil3.53%
iShares Large Cap Value Active ETF
Anteil2.45%
Global X S&P 500 Quality Dividend ETF
Anteil2%
iShares U.S. Medical Devices ETF
Anteil1.92%
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.76%
SPDR S&P Health Care Equipment ETF
Anteil1.52%
First Trust Indxx Medical Devices ETF
Anteil1.27%
ROBO Global Healthcare Technology & Innovation ETF
Anteil0.98%
Humankind US Stock ETF
Anteil0.85%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
2.75B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Feb 11, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Apr 01, 2025 going ex on Feb 28, 2025 with reinvestment option
Feb 28, 2025
Apr 01, 2025
Feb 28, 2025
Nov 11, 2024
BAX.NB Final Cash Dividend of gross USD 0.17 paid on Jan 02, 2025 going ex on Nov 29, 2024 with reinvestment option
Nov 29, 2024
Jan 02, 2025
Nov 29, 2024
Jul 16, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 01, 2024 going ex on Aug 30, 2024 with reinvestment option
Aug 30, 2024
Oct 01, 2024
Aug 30, 2024
May 07, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Jul 01, 2024 going ex on May 31, 2024 with reinvestment option
May 31, 2024
Jul 01, 2024
May 31, 2024
Feb 12, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Apr 01, 2024 going ex on Feb 29, 2024 with reinvestment option
Mar 01, 2024
Apr 01, 2024
Feb 29, 2024
Nov 14, 2023
BAX.NB Final Cash Dividend of gross USD 0.29 paid on Jan 02, 2024 going ex on Nov 30, 2023 with reinvestment option
Dec 01, 2023
Jan 02, 2024
Nov 30, 2023
Jul 18, 2023
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 02, 2023 going ex on Aug 31, 2023 with reinvestment option
Sep 01, 2023
Oct 02, 2023
Aug 31, 2023
May 01, 2023
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Jul 03, 2023 going ex on Jun 01, 2023
Jun 02, 2023
Jul 03, 2023
Jun 01, 2023
Feb 14, 2023
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Apr 03, 2023 going ex on Feb 23, 2023 with reinvestment option
Feb 24, 2023
Apr 03, 2023
Feb 23, 2023
Nov 15, 2022
BAX.NB Final Cash Dividend of gross USD 0.29 paid on Jan 03, 2023 going ex on Dec 01, 2022
Dec 02, 2022
Jan 03, 2023
Dec 01, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten